Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods [Benzinga]
Wednesday, May 8, 2024 1 min read
Key Takeaway: Enveric Biosciences has signed a non-binding term sheet for an exclusive license with an undisclosed biotech company. This deal involves two patented methods that combine cannabinoids with chemotherapy to treat breast cancer and other cancers. The financial terms of the agreement are valued at $61 million.
Price reaction · baseline $160.2 (2024-05-07 close) · hit pre-market · 1 other ENVB headline(s) in the window, move may be shared
day 0 close
+10.1%
day 1
+3.4%
day 3
-5.6%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences has secured a significant $61M license deal.
The patented methods aim to enhance breast cancer treatment.
Combination of cannabinoids with chemotherapy presents innovative potential.
Full Press Release Details
Enveric Biosciences, a Nasdaq-listed psychedelics biotech firm, has entered into a non-binding term sheet with an undisclosed biotech company (licensee) for an exclusive license to two patented methods aimed at treating breast cancer and other cancers. These methods utilize cannabinoids in combination with chemotherapeutic drugs.
Full Article >>
Frequently Asked Questions
What is the value of the license deal signed by Enveric?
The license deal is valued at $61 million.
What methods are included in the license agreement?
The agreement includes two patented methods for treating breast cancer.
How do the patented methods work?
They utilize cannabinoids in combination with chemotherapeutic drugs.